Biosensor Surface Layer for Uniform Antibody Immobilization

The patent replaces the liquid phase surface treatment method with a vapor phase deposition method. Specifically, the support layer is formed by vapor deposition of silane compounds, which then undergo condensation to create a uniform self-assembled monolayer. This phase change from liquid to vapor enables more uniform distribution and positioning of the support layer, resolving the contradiction between ease of manufacture and manufacturing precision.

The patent utilizes phase transitions in the deposition process. The silane compound is deposited from vapor phase onto the base material, then undergoes condensation phase transition to form the self-assembled monolayer. This controlled phase transition ensures uniform formation of the support layer with consistent thickness and composition, achieving high manufacturing precision while maintaining ease of operation through a straightforward vapor deposition process.

The patent substitutes liquid phase treatment with vapor phase deposition to form the support layer. This replacement maintains operational simplicity through a single-step vapor deposition process while dramatically improving measurement precision. The vapor deposited support layer provides uniform antibody immobilization, resulting in enhanced detection sensitivity for the target substance.

The vapor deposition and condensation phase transition creates a highly uniform support layer structure that maximizes antibody immobilization density and uniformity. This uniform structure directly improves the detection sensitivity and measurement precision of the biosensor, while the vapor phase process remains as operationally simple as the liquid phase method it replaces.

The patent replaces liquid phase surface treatment with vapor phase deposition to form the self-assembled monolayer. This substitution achieves superior detection sensitivity through uniform antibody immobilization while maintaining ease of manufacture. The vapor deposition process is operationally simple, requiring only deposition of the silane compound followed by automatic self-assembly, making it as easy to manufacture as liquid phase methods while delivering superior performance.

The vapor deposition and condensation phase transition creates a highly uniform self-assembled monolayer that maximizes detection sensitivity. The process remains easy to manufacture because it follows a simple sequence: vapor deposition of silane, condensation to form self-assembled monolayer, and antibody immobilization. The phase transition mechanism ensures uniformity without requiring complex process control.